Fed. Circ. Revives 5 Mylan Drug Patents In Sunovion Row
The appellate ruling reversed a New York federal judge's finding last year that the five patents were invalid because Sunovion had conducted clinical trials on Brovana prior to Mylan's applications. The judge said at the time that the trials constituted “public use” of the invention, which precludes patentability.
On Monday, the panel...
To view the full article, register now.